Multiple Myeloma Therapy: Highlights from #ASCO and #EHA2025 – Wednesday, July 2, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content Multiple Myeloma Therapy: Highlights from #ASCO and #EHA2025 – Wednesday, July 2, 2025 Read More »
Multiple Myeloma Academy: IACH Journal Club – Tuesday, July 1, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content Multiple Myeloma Academy: IACH Journal Club – Tuesday, July 1, 2025 Read More »
IACH Post ASCO EHA COMy Roundtable Discussion – Wednesday, June 25, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content IACH Post ASCO EHA COMy Roundtable Discussion – Wednesday, June 25, 2025 Read More »
My Story and Advocacy Efforts – Tuesday, June 3, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content My Story and Advocacy Efforts – Tuesday, June 3, 2025 Read More »
To Pee or Not to Pee: Prine Testing in Myeloma Response Evaluations – Monday, May 5, 2025 CME credits / Sharon Rawet Lederer Open to access this content To Pee or Not to Pee: Prine Testing in Myeloma Response Evaluations – Monday, May 5, 2025 Read More »
IACH Roundtable Debate – Transplant at 65+: A Still Valid Strategy or a Risk We Should Retire? – Monday, April 7, 2025 Uncategorized / Yaniv Kalif Open to access this content IACH Roundtable Debate – Transplant at 65+: A Still Valid Strategy or a Risk We Should Retire? – Monday, April 7, 2025 Read More »
IACH Journal Club-Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial – Monday, March 24, 2025 CME credits / Adam Barkay Open to access this content IACH Journal Club-Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial – Monday, March 24, 2025 Read More »
